Trial · NCT04969991
Results by group32
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 32
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Proportion of Participants Alive and Free of Respiratory Failure at Day 28 | Varespladib: 250 mg QD + Placebo + Placebo | 4 | Participants | ||
| Proportion of Participants Alive and Free of Respiratory Failure at Day 28 | Varespladib: 250 mg BID + Placebo | 4 | Participants | ||
| Proportion of Participants Alive and Free of Respiratory Failure at Day 28 | Varespladib: 250 mg TID | 3 | Participants | ||
| Proportion of Participants Alive and Free of Respiratory Failure at Day 28 | Placebo | 3 | Participants | ||
| Proportion of Subjects Using HFNC Within the First 28 Days After Randomization | Varespladib: 250 mg QD + Placebo + Placebo | 0 | Participants | ||
| Proportion of Subjects Using HFNC Within the First 28 Days After Randomization | Varespladib: 250 mg BID + Placebo | 1 | Participants | ||
| Proportion of Subjects Using HFNC Within the First 28 Days After Randomization | Varespladib: 250 mg TID | 2 | Participants | ||
| Proportion of Subjects Using HFNC Within the First 28 Days After Randomization | Placebo | 0 | Participants | ||
| Proportion of Subjects Using Noninvasive Respiratory Support Within the First 28 Days After Randomization | Varespladib: 250 mg QD + Placebo + Placebo | 1 | Participants | ||
| Proportion of Subjects Using Noninvasive Respiratory Support Within the First 28 Days After Randomization | Varespladib: 250 mg BID + Placebo | 1 | Participants | ||
| Proportion of Subjects Using Noninvasive Respiratory Support Within the First 28 Days After Randomization | Varespladib: 250 mg TID | 0 | Participants | ||
| Proportion of Subjects Using Noninvasive Respiratory Support Within the First 28 Days After Randomization | Placebo | 0 | Participants | ||
| Proportion of Subjects Using Mechanical Ventilation Within the First 28 Days After Randomization | Varespladib: 250 mg QD + Placebo + Placebo | 1 | Participants | ||
| Proportion of Subjects Using Mechanical Ventilation Within the First 28 Days After Randomization | Varespladib: 250 mg BID + Placebo | 0 | Participants | ||
| Proportion of Subjects Using Mechanical Ventilation Within the First 28 Days After Randomization | Varespladib: 250 mg TID | 1 | Participants | ||
| Proportion of Subjects Using Mechanical Ventilation Within the First 28 Days After Randomization | Placebo | 0 | Participants | ||
| Number of Days of Oxygen Support Through Day 28 After Randomization | Varespladib: 250 mg QD + Placebo + Placebo | 9 | Standard Deviation 11 | days | |
| Number of Days of Oxygen Support Through Day 28 After Randomization | Varespladib: 250 mg BID + Placebo | 6 | Standard Deviation 8 | days | |
| Number of Days of Oxygen Support Through Day 28 After Randomization | Varespladib: 250 mg TID | 12 | Standard Deviation 11 | days | |
| Number of Days of Oxygen Support Through Day 28 After Randomization | Placebo | 11 | Standard Deviation 15 | days |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04969991/results